Glymin 500mg Tablet SR contains Metformin hydrochloride, an oral antihyperglycemic agent used primarily in the management of type 2 diabetes mellitus. Metformin belongs to the biguanide class and functions by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity by enhancing peripheral glucose uptake and utilization. Glymin 500mg Tablet SR is formulated as a sustained-release tablet to provide a gradual release of the active ingredient, thereby minimizing gastrointestinal side effects commonly associated with immediate-release formulations and improving patient compliance. This medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly in overweight patients or those with insulin resistance. It may be used as monotherapy or in combination with other antidiabetic agents, including insulin. Glymin 500mg Tablet SR should be administered with meals to reduce gastrointestinal discomfort. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal discomfort, and a metallic taste. Rare but serious adverse effects include lactic acidosis, especially in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Glymin 500mg Tablet SR is contraindicated in patients with severe renal impairment, acute metabolic acidosis, or hypersensitivity to metformin.